OncoMatch/Clinical Trials/NCT07295262
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
Is NCT07295262 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies ICG-Cisplatin Nanoprobe (NIR-II NanoM) for liver cancer, adult.
Treatment: ICG-Cisplatin Nanoprobe (NIR-II NanoM) — This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Lab requirements
Kidney function
Severe renal dysfunction excluded.
Liver function
Child-Pugh Class A liver function. Child-Pugh score > 7 excluded.
Cardiac function
Severe cardiac dysfunction excluded.
Child-Pugh Class A liver function. Child-Pugh score > 7 excluded. Severe cardiac, pulmonary, or renal dysfunction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify